Several clinical studies have shown that MPN patients express increased levels of inflammatory mediators75, including the key inflammatory cytokine interleukin-8 (IL-8), the plasma levels of which predict adverse clinical outcomes76. The gene discussed is CXCL8; the disease is myeloproliferative neoplasm.